TY - JOUR
T1 - Advances in diagnosis and management of distal sensory polyneuropathies
AU - Silsby, Matthew
AU - Feldman, Eva L.
AU - Dortch, Richard D.
AU - Roth, Alison
AU - Haroutounian, Simon
AU - Rajabally, Yusuf A.
AU - Vucic, Steve
AU - Shy, Michael E.
AU - Oaklander, Anne Louise
AU - Simon, Neil G.
PY - 2023/12/1
Y1 - 2023/12/1
N2 - Distal sensory polyneuropathy (DSP) is characterised by length-dependent, sensory-predominant symptoms and signs, including potentially disabling symmetric chronic pain, tingling and poor balance. Some patients also have or develop dysautonomia or motor involvement depending on whether large myelinated or small fibres are predominantly affected. Although highly prevalent, diagnosis and management can be challenging. While classic diabetes and toxic causes are well-recognised, there are increasingly diverse associations, including with dysimmune, rheumatological and neurodegenerative conditions. Approximately half of cases are initially considered idiopathic despite thorough evaluation, but often, the causes emerge later as new symptoms develop or testing advances, for instance with genetic approaches. Improving and standardising DSP metrics, as already accomplished for motor neuropathies, would permit in-clinic longitudinal tracking of natural history and treatment responses. Standardising phenotyping could advance research and facilitate trials of potential therapies, which lag so far. This review updates on recent advances and summarises current evidence for specific treatments.
AB - Distal sensory polyneuropathy (DSP) is characterised by length-dependent, sensory-predominant symptoms and signs, including potentially disabling symmetric chronic pain, tingling and poor balance. Some patients also have or develop dysautonomia or motor involvement depending on whether large myelinated or small fibres are predominantly affected. Although highly prevalent, diagnosis and management can be challenging. While classic diabetes and toxic causes are well-recognised, there are increasingly diverse associations, including with dysimmune, rheumatological and neurodegenerative conditions. Approximately half of cases are initially considered idiopathic despite thorough evaluation, but often, the causes emerge later as new symptoms develop or testing advances, for instance with genetic approaches. Improving and standardising DSP metrics, as already accomplished for motor neuropathies, would permit in-clinic longitudinal tracking of natural history and treatment responses. Standardising phenotyping could advance research and facilitate trials of potential therapies, which lag so far. This review updates on recent advances and summarises current evidence for specific treatments.
KW - NEUROGENETICS
KW - NEUROIMMUNOLOGY
KW - NEUROMUSCULAR
KW - NEUROPATHY
KW - PERIPHERAL NEUROPATHOLOGY
UR - http://www.scopus.com/inward/record.url?scp=85152210629&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2021-328489
DO - 10.1136/jnnp-2021-328489
M3 - Review article
C2 - 36997315
AN - SCOPUS:85152210629
SN - 0022-3050
VL - 94
SP - 1025
EP - 1039
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 12
ER -